New vaccine trial hopes to train immune system to attack Triple-Negative breast cancer
NCT ID NCT07078604
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study tests a vaccine called STEMVAC, given with chemotherapy, for people with a type of advanced breast cancer (triple-negative) that has spread. The vaccine is designed to teach the body's immune system to find and destroy cancer stem cells. About 20 adults with PD-L1 negative tumors will take part to see if the vaccine triggers an immune response and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Blood test could help doctors switch cancer drugs faster
- Can couples coping together ease the burden of advanced cancer?
- Blood test could track breast cancer in real time